WO2016052947A1 - 건성 치료용 산성 외용제 조성물 - Google Patents

건성 치료용 산성 외용제 조성물 Download PDF

Info

Publication number
WO2016052947A1
WO2016052947A1 PCT/KR2015/010191 KR2015010191W WO2016052947A1 WO 2016052947 A1 WO2016052947 A1 WO 2016052947A1 KR 2015010191 W KR2015010191 W KR 2015010191W WO 2016052947 A1 WO2016052947 A1 WO 2016052947A1
Authority
WO
WIPO (PCT)
Prior art keywords
psoriasis
skin
day
comparative example
average
Prior art date
Application number
PCT/KR2015/010191
Other languages
English (en)
French (fr)
Inventor
김성우
정세규
이신희
김수환
Original Assignee
(주)네오팜
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by (주)네오팜 filed Critical (주)네오팜
Publication of WO2016052947A1 publication Critical patent/WO2016052947A1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles

Definitions

  • the present invention is a composition for the treatment of psoriasis, which relates to a pharmaceutical composition whose pH is controlled by an acidic polymer compound.
  • Psoriasis is a chronic inflammatory skin disease, usually in the elbows, knees, scalp, nails, toenails, or torso, and is a chronic skin disease in which the development of silvery-skinned spot papules is characteristic. It may be psoriasis, epidermal psoriasis or pustulic psoriasis, and may occur locally or occur throughout the body, which may lead to severity and may be accompanied by complications.
  • Korean Patent No. 0634397 provides a composition for treating psoriasis, a composition containing several components in a specific ratio, and Korean Patent No. 1374907 provides alpha 2 adrenergic receptors for treating psoriasis-related symptoms. The effectiveness of this drug and its potential as a treatment for psoriasis-related diseases are described.
  • the present invention is a composition for treating psoriasis by regulating pH to acidity, and the invention of a composition for treating psoriasis by adjusting pH like the present invention is unknown.
  • the present invention provides a composition for treating psoriasis, specifically acidic. It is to provide a pharmaceutical external preparation composition of pH 3.0 to 5.0 phosphoric acid by adjusting the pH with a high molecular compound.
  • the present invention provides a pharmaceutical external composition for treating psoriasis containing an acidic polymer compound.
  • the present invention provides a psoriasis therapeutic pharmaceutical external composition whose pH is controlled to 3.0 to 5.0 by the amount of acidic polymer compound.
  • the present invention is to adjust the pH of the carbomer (carbomer) having a carboxyl group, to provide a pharmaceutical external composition of pH 3.0-5.0.
  • 3 shows the change in the thickness of the ear skin of the mouse at 8th, 10th and 12th days.
  • FIG. 4 shows changes in skin moisture evaporation of mice on days 8, 10 and 12.
  • FIG. 5 shows changes in the skin moisture content of mice on days 8, 10, and 12.
  • FIG. 6 shows a change in the back tissue weight of a mouse.
  • the left bar shows the weight of the left ear.
  • Figure 11 shows the thickness of the epidermal epidermal layer of the mouse.
  • FIG. 12 shows the results of observing the thicknesses of the back tissues (A) and ear tissues (B) of Comparative Example 1.
  • FIG. 12 shows the results of observing the thicknesses of the back tissues (A) and ear tissues (B) of Comparative Example 1.
  • FIG. 13 shows the results of observing the thicknesses of the back tissues (A) and ear tissues (B) of Comparative Example 2.
  • FIG. 13 shows the results of observing the thicknesses of the back tissues (A) and ear tissues (B) of Comparative Example 2.
  • FIG. 14 shows the results of observing the thicknesses of the back tissues (A) and ear tissues (B) of Example 1.
  • FIG. 14 shows the results of observing the thicknesses of the back tissues (A) and ear tissues (B) of Example 1.
  • FIG. 15 shows the results of observing the thicknesses of the back tissues (A) and ear tissues (B) of Example 2.
  • FIG. 15 shows the results of observing the thicknesses of the back tissues (A) and ear tissues (B) of Example 2.
  • FIG. 16 shows the results of observing the thicknesses of the back tissues (A) and ear tissues (B) of Example 3.
  • FIG. 16 shows the results of observing the thicknesses of the back tissues (A) and ear tissues (B) of Example 3.
  • FIG. 17 shows the results of observing the thicknesses of the back tissues (A) and ear tissues (B) of Example 4.
  • FIG. 17 shows the results of observing the thicknesses of the back tissues (A) and ear tissues (B) of Example 4.
  • FIG. 18 shows the results of observing the thicknesses of the back tissues (A) and ear tissues (B) of Example 5.
  • FIG. 18 shows the results of observing the thicknesses of the back tissues (A) and ear tissues (B) of Example 5.
  • the present invention provides a pharmaceutical external composition for treating psoriasis.
  • Psoriasis prosiasis
  • psoriasis is a common condition known as psoriasis and its symptoms.
  • Psoriasis is a chronic inflammatory skin disease characterized by epidermal growth and inflammation of the dermis, with reddening of the skin at the onset and the appearance of silvery scales on the skin. Eulyang, ulcerative and hemorrhagic dryness.
  • An acidic polymer compound is a polymer compound containing an acidic functional group.
  • the acidic polymeric compound is preferably carbomer or carbopol. According to one embodiment of the present invention, acrylic acid is synthesized as a monomer to form a carboxyl group.
  • the pH of the composition can be adjusted according to the amount of carbomer, an acidic polymer compound having
  • the composition for treating psoriasis for treating psoriasis is a composition having a specific pH, wherein the pH is 3.0 to 5.0, 3.1 to 4.9, 3.2 to 4.8, 3.3 to 4.7, 3.4 to 4.6, 3.5 to 4.5, 3.6 to 4.4, 3.7 to 4.3 , 3.8 to 4.2, 3.9 to 4.1, 3.1 to 3.9, 3.2 to 3.8, 3.3 to 3.7, 3.4 to 3.6.
  • the external composition of the above pH range is applied to psoriasis-induced skin to confirm the psoriasis treatment effect due to the pH drop. can do. If the pH is lower than 3.0, it may cause a cosmetic problem, it is difficult to conduct animal experiments, and even when used as an external preparation, the skin may be adversely affected.
  • the pH range specified by the Food and Drug Administration's Cosmetic Standards and Test Methods is outside the pH range of 3.0 to 9.0, and external application for skin with a pH of less than 3.0 has no meaning experimentally or commercially.
  • External preparations are used on the outside of the human body, and may include ointments, lotions, creams, etc., depending on the type of formulation, but are not limited depending on the type, as long as they can be used for external therapy.
  • pH, water content, mass mass should be considered, and can be formulated into oil-based, oil-based, water-based and suspending columns such as petroleum jelly, paraffin, plastic, lard, silicone, vegetable oil, wax, lanolin, etc. It may contain additives such as moisturizers, solubilizers, softening aids, etc.
  • lotions When formulated into lotions, it may be formulated into solution bases, suspension bases and emulsion bases and may contain humectants such as glycerin and glycols.
  • Psoriasis induction can be carried out by spreading imiquimod creams on the skin.
  • Psoriasis induced by imiquimod has clinical, histological and immunological changes in
  • the psoriasis model induced by imiqui mode was used to check the effect of the external composition for psoriasis treatment, but it is also not limited to this, and can also be applied to the skin of psoriasis patients.
  • the external composition for treating psoriasis for acid is decreased in the skin area of the psoriasis-induced skin, the back and ear psoriasis-derived epidermal layer thickness, moisture evaporation, and water content are increased. And the weight loss of psoriasis tissue was able to confirm the effect.
  • component of pH 3.5 for external application is the same as Table 1 below, by controlling the carbomer and water was used to prepare a dispersible preparation for external use of pH 3.0 ⁇ 5.0 in the same component.
  • 1,2-nucleic acid diol 40% (1,2-Hexanediol), caprylyl glycol 0.60 40% (Caprylyl glycol), tropolone 20% (Tropolone)
  • Myristoyl / palmitoyloxostearamide / arachamide 0.30 MEA Myristoyl / palmitoyloxostearamide / arachamide MEA
  • Xanthan gum 0.05 Tocopheryl acetate 0.10 Methylbenzylmethylbenkimidacolpiperidinylpetanone (Methylbenzylmethy 0.05 lbenzimidazolepiperidinylmethanone)
  • a 7-week-old female mouse (Balb / c) was prepared for 1 week in constant temperature and humidity conditions for the production of psoriasis-induced mice.
  • (imiquimod, Aldara®) 62.5 mg of 5% cream was also applied to the back and right ear. After 2 days, Imiquimod 5% cream was applied to the back and right ear for 5 days at 62.5 mg daily for 5 days.
  • TEWL trans epidermal water loss
  • hydration skin moisture
  • mice The body weights, skin level evaporation, skin moisture content, and skin thickness of the horn and ears were measured and divided into groups similar to the mean values. A total of 7 groups of 5 mice were used in each group. The normal mouse group vehicle group 1 (Comparative Example 1) and no treatment to the psoriasis-induced mouse
  • the condition was checked by measuring the body weight, skin moisture evaporation, skin moisture and skin thickness of the back and ears at the 8th, 10th, and 12th day of the experiment, and from the 12th day of the end of the experiment, the skin pH and erytheme were measured. ) To confirm the condition.
  • Example 1 18.90 19.98 22.31
  • Example 1 18.60 19.89 21.56
  • Example 1 18.90 19.88 20.14
  • Example 1 18.80 20.34 21.81
  • Table 2 and Figure 1 show the mouse's weight (g), which showed a slight weight loss in the IMQ-treated group, but not a significant difference.
  • Example 1 33.50 29.30 25.30
  • Example 1 35.40 28.30 20.40
  • Example 1 35.80 19.80 15.40
  • Example 1 34.50 24.50 18.80
  • Table 3 and Figure 2 shows the skin moisture evaporation (g / cnf / hr) in Comparative Example 2 treated IMQ was 5 times more skin moisture evaporation than Comparative Example 1 on day 8, Example 2, Example Near-normal values were seen in 3 and Example 4, and the most effective in Example 3. The significant increase was confirmed in all of Examples 1-5.
  • Table 4 and FIG. 3 show skin moisture content (AU), and Comparative Example 2 treated with IMQ reduced the skin moisture content by three times or more than Comparative Example 1.
  • Example 2 Example 3, and Example A value close to normal was shown in Fig. 4, and the best effect was obtained in Example 3. A significant increase was confirmed in all of Examples 1 to 5.
  • Example 1 0.68 0.55 0.49
  • Example 1 0.73 0.51 0.36
  • Example 1 0.69 0.49 0.33
  • Example 1 0.68 0.53 0.33
  • Table 5 and FIG. 4 show round thickness ⁇ m), and Comparative Example 2 treated with IMQ was three times thicker than Comparative Example 1, and thicknesses close to normal in Examples 2, 3, and 4 The most effective result was shown in Example 3. Significant decrease was confirmed in all of Examples 1-5.
  • Comparative Example 2 which processed IMQ is 3 times more than Comparative Example 1.
  • Table 7 and Figure 6 show the weight (mg) of the tissues taken after the end of the experiment, and the weight was reduced compared to Comparative Example 2 treated with IMQ in Examples 1 to 5.
  • Example 2 Example 3 and Example The closest normal value was shown in Example 4, and the most effective was obtained in Example 3. A significant decrease was confirmed when compared with Comparative Example 2 in all of Examples 1 to 5.
  • Tables 8 and 7 show the weight (mg) obtained after the end of the experiment, and when compared with the right ear, Examples 1 to 5 reduced the weight than Comparative Example 2 treated with 11 ( 3). 2, Examples 3 and 4 showed a near-normal value, and when compared with Comparative Example 2 in all of Examples 1 to 5 was confirmed a significant decrease.
  • Table 9 and Figure 8 show the skin pH, the pH was reduced in Examples 1 to 5, except for Example 5 all showed a significant decrease in milk, the value closest to the normal in Example 3 Appeared.
  • Table 10 and Figure 9 are measured the degree of erythema using a color difference meter, the degree of flare is hardly distinguished by the naked eye or reduced numerically, the significance was shown in Examples 3 and 4.
  • Table 11 and Fig. 10 show the thickness of the epidermis (n) through H & E staining. The thickness of the epidermal layer was measured at six different points after photographing the dyed tissue sample. Compared with Comparative Example 2 treated with IMQ, Examples 1 to 5 showed significant decreases, and near-normal values were shown in Examples 3, 4 and 5, and the best effect in Example 3 was obtained. Confirmed. Table 12
  • Table 12 and FIG. 11 show the thickness of the epidermis mi) through H & E staining.
  • the thickness of the epidermis was measured at six different points after photographing the dyed tissue sample pole. Compared with Comparative Example 2 treated with IMQ, Examples 1 to 5 showed a significant decrease, and the closest normal values were found in Examples 3, 4, and 5, and the highest in Example 3. Excellent effect was confirmed.
  • Table 13 shows the significance of each of the quantitative measurements taken in Comparative Examples 1 and 2 and Examples 1 to 5, in particular, Examples 1 to 5 were more significant at all values compared to Comparative Example 2, which only processed IMQ. Worked.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

본 발명은 건선 치료용 약학적 조성물에 관한 발명으로서，산성 고분자화합물에 의해 pH가 산성으로 조절되는 것을 특징으로 하며，건선이 유발된 피부의 표피층의 두께 감소, 수분 증가 및 유지 등 건선 치료에 효과적인 새로운 건선 치료용 조성물을 제공한다.

Description

명세서
발명의명칭:건성치료용산성외용제조성물 기술분야
[1] 본발명은건선치료를위한조성물로서 ,산성의고분자화합물에의해 pH가 조절되는약학적조성물에관한발명이다.
배경기술
[2] 건선은만성염증성피부질환으로주로팔꿈치，무릎，두피,손톱,발톱또는 몸통에서발생되며은색으로벗겨지는반점구진의발생이특짚인만성적 피부질환이다ᅳ통상적인형태는심상성건선，물방을양건선，흥피성건선또는 농포성건선등이고국소적으로가볍게발생하거나신체전체에발생하여 중증도에이를수있고합병증을동반할수도있다.
[3] 건선의발생원인에대한연구는활발히진행되고있으나아직명확하게
밝혀져있지않다.유전적,환경적，약물，피부자극,스트레스둥이주요 원인이며,피부의 T세포，수지상세포，호중구등의면역세포가분비하는 면역물질들의여러기전을통해피부의각질세포를자극하여각질세포의 과다한증식및염증둥으로건선이발생하는것으로생각되고있다.
[4] 건선의치료에는발병부위에직접약을바르거나，자외선등을이용한
광화학적치료,약물을주사또는경구섭취가능한약을복용하는등여러 방법이이용되고있다.직접바르는약은주로스테로이드를포함하는크림이나 연고로서내성이발생할수있고,광화학적치료는피부의노화나피부암 발생률을증가시킬수있다.또한，주사또는경구섭취치료제의경우면역세포 활성의억계，간경화，섬유증등의부작용이있는것으로알려져있다.이러한 부작용의개선을위해생물학적제제를건선치료제로개발하는연구도 활발하나，건선의뚜렷한완치및재발을방지하는치료제또는방법은아직 없는실정이다.
[5] 한국등록특허 0634397은여러성분이특정비로흔합된조성물을건선치료용 조성물로제공하고있고,한국등록특허 1374907은알파 2아드레날린성 수용체를건선관련증상치료제로제공하고있고,육안적인증상완화의효과나 건선관련질환의치료제로서의가능성정도가기재되어있다.
[6] 본발명은 pH를산성으로조절하여건선을치료하는조성물에대한발명으로, 본발명과같이 pH조절을통해건선을치료하는조성물에대한발명은알려진 바없다.
[7]
발명의상세한설명
기술적과제
[8] 본발명은건선치료를위한조성물을제공하는것으로，구체적으로산성 고분자화합물로 pH를조절하여 pH가 3.0내지 5.0인산성의약학적외용제 조성물을제공하는것이다.
과제해결수단
[9] 본발명은산성고분자화합물이포함된건선치료용약학적외용제조성물을 제공한다.
[10] 본발명은산성고분자화합물의함량에의해 pH가 3.0내지 5.0로조절되는 건선치료용약학적외용제조성물을제공한다.
[11] 본발명은카르복실기를가지는카보머 (carbomer)의 pH가조절되어 , pH가 3.0 내지 5.0인산성의약학적외용제조성물을제공한다.
발명의효과
[12] 산성고분자화합물을포함하는 pH 3.0내지 5.0인약학적외용제조성물처리 건선에의한피부두께의감소，피부수분증발량의감소，피부수분량의증가및 피부조직의무게감소측정을통해건선치료에효과가있음을알수있다. 도면의간단한설명
[13] 도 1은 8일， 10일, 12일째마우스의체중변화를나타낸다.
[14] 도 2는 8일， 10일， 12일째마우스의등피부두께변화를나타낸다.
[15] 도 3은 8일， 10일, 12일째마우스의귀피부두께변화를나타낸다.
[16] 도 4는 8일， 10일， 12일째마우스의피부수분증발량변화를나타낸다.
[17] 도 5는 8일, 10일, 12일째마우스의피부수분함량변화를나타낸다.
[18] 도 6은마우스의등조직무게변화를나타낸다.
[19] 도 7은마우스의귀조직무게변화를나타낸것으로왼쪽막대는왼쪽귀의 무게를나타낸다.
[20] 도 8은마우스의피부 pH변화를나타낸다
[21] 도 9는마우스의홍반측정결과를나타낸다.
[22] 도 10은마우스와등조직표피층두께변화를나타낸다.
[23] 도 11은마우스의귀조직표피층두께변화를나타낸다.
[24] 도 12는비교예 1의등조직 (A),귀조직 (B)의두께를관찰한결과이다.
[25] 도 13는비교예 2의등조직 (A),귀조직 (B)의두께를관찰한결과이다.
[26] 도 14는실시예 1의등조직 (A),귀조직 (B)의두께를관찰한결과이다.
[27] 도 15는실시예 2의등조직 (A),귀조직 (B)의두께를관찰한결과이다.
[28] 도 16는실시예 3의등조직 (A),귀조직 (B)의두께를관찰한결과이다.
[29] 도 17는실시예 4의등조직 (A),귀조직 (B)의두께를관찰한결과이다.
[30] 도 18는실시예 5의등조직 (A)，귀조직 (B)의두께를관찰한결과이다.
발명의실시를위한최선의형태
[31] 이하에서본발명에대하여구체적으로상세히설명하고자한다.본
명세서에서사용되는용어는따로정의하지않는경우해당분야에서통상의 지식을가진자가일반적으로이해하는내용으로해석되어야할것이다.본 명세서의도면및실시예는통상의기술자가본발명을쉽게이해하고실시하기 위한것으로도면및실시예에서발명의요지를흐릴수있는내용은생략될수 있으며，본발명이도면및실시예로한정되는것은아니다.
[32] 본발명은건선치료용약학적외용제조성물을제공하는것으로,산성의
고분자화합물이포함되고,상기산성의고분자화합물에의해 pH가 3.0내지 5.0로조절되는건선치료용약학적외용제조성물이다.
[33] 건선 (prosiasis)은일반적으로알려진건선，이의증상을가지는질환을
포함한다할것이다.건선은만성염증성피부질환으로,조직학적으로표피의 증식및진피의염증이특징이며，발병시피부가붉게변하고은빛의비늘과 같은피부각질이관찰되며발병형태에따라심상성 ,물방을양，농포성및 흥피성건성등이있다.
[34] 산성고분자화합물은산성을띠는작용기를포함하는고분자화합물로서
약학적조성물에포함되어사용할수있는것이면제한되지않는다.상기산성 고분자화합물은바람직하게는카보머 (carbomer)또는카보폴 (carbopol)이다.본 발명의일실시예에따르면,아크릴산을단량체로증합되어카르복시기를 가지는산성고분자화합물인카보머의함량에따라조성물의 pH가조절될수 있다.
[35] 건선치료용약학적외용제조성물은특정 pH를가지는조성물로서상기 pH는 3.0내지 5.0, 3.1내지 4.9, 3.2내지 4.8, 3.3내지 4.7， 3.4내지 4.6， 3.5내지 4.5, 3.6 내지 4.4， 3.7내지 4.3， 3.8내지 4.2， 3.9내지 4.1， 3.1내지 3.9， 3.2내지 3.8， 3.3 내지 3.7， 3.4내지 3.6일수있다.상기 pH범위의외용제조성물이건선유발 피부에도포되어 pH의저하에따른건선치료효과를확인할수있다. pH가 3.0 미만의경우제형상문제가발생할수있고동물실험의진행이어려우며， 외용제로사용하는경우에도피부에악영향을미치게된다.또한，
건선치료용으로식품의약품안전처의화장품기준및시험방법에서명시하는 pH 범위인 3.0내지 9.0을벗어나게되어 pH가 3.0미만의피부도포용외용제는 실험적으로든상업적으로든의미가없게된다.
[36] 외용제는인체의외부에사용하는것으로，제형화형태에따라연고，로션,크림 등이있을수있으나외용요법으로사용될수있는것이라면형태에따라 제한되지않는다.연고제로제형화하는경우피부은도， pH,수분량,지질량둥이 고려되야하고바셀린，파라핀，플라스틱，라드，실리콘，식물성오일，왁스， 라놀린등의유지성기제，유제성기제,수용성기제및현탁성기제둥으로 제형화될수있으며산화방지제，방부제，보습제,용해보조제，연화보조제등의 첨가제를포함할수있다.로션제로제형화하는경우용액형기제,현탁형기제 및유제형기제등으로제형화될수있고글리세린,글리콜같은습윤제가 포함될수있다.
[37] 건선유발은이미퀴모드 (imiquimod)크림을피부에도포하여수행할수있다. 이미퀴모드에의해유발된건선은임상적，조직학적및면역학적변화가건선의 병태생리와동일하게나타낸다.본발명에서건선치료용외용제조성물의 효과를확인하기위해이미퀴모드로유발된건선모델을사용하였으나이에 제한되지않고，건선염환자의피부에도포하여확인할수도있다.
[38] 본발명의일실시예에따르면，산성의건선치료용외용제조성물을건선유발 피부에도포시피부의 pH가감소하고，등및귀의건선유발표피층두께감소, 수분증발양의감소，수분함량증가및건선조직의무게감소를통해효과를 확인할수있었다.
[39] 이하에서본발명인건선치료용외용제조성물에대한실시예를통해보다 구체적으로설명하며，본발명이하기실시예에의해제한되는것은아니다.
[40]
발명의실시를위한형태
[41] [실시예 1 ~ 5]
[42] 피부도포용산성외용제제조
[43] 피부도포용외용제제조는피부에도포가용이한크림의형태로제조를
하였다 . pH 3.5외용제의성분은아래 [표 1]과같고，카보머및물을조절하여 : 동일성분으로 pH 3.0~5.0의산성외용제를제조하여사용하였다.
[44] 표 1
[Table 1]
성부 함량 (g) 물 (Water) 77.70 글리세린 (Glycerin) 4.20 세테아릴알콜 (Cetearyl alcohol) 3.50 부틸렌글라이콜 (Butylene glycol) 3.00 카프릴릭 /카프릭트리글리세라이드 (Caprylic/capric triglyceride) 2.50 포도씨오일 (Vitisinifera seed oil) 2.50 글리세릴스테아레이트 (Glyceryl stearate) 1.50 폴리글리세릴 -10디스테아레이드 (Polyglyceryl-10 distearate) 1.00
1,2-핵산다이올 40%(1,2-Hexanediol),카프릴릴글라이콜 0.60 40%(Caprylyl glycol),트로폴론 20%(Tropolone)
스테아르산 (Stearic acid) 0.90 유차나무씨오일 (Camellia oleifera seed oil) 0.50 폴리글리세릴 -3메틸글로코스디스테아레이트 80%(Polyglyceryl-3 0.50 methylglucosedistearate),글리세릴스테레이트 SE 10%(glyceryl
stearate SE),메틸글루코스세스퀴스테아레이트 10%(methyl
glucose sesquistearate)
디메치콘 (Dimethicone) 0.40 하이드로제네이트폴리 (C6-14올레핀) (Hydrogenated poly (C6-14 0.40 olefin))
미리스토일 /팔미토일옥소스테아라마이드 /아라카마이드 0.30 MEA(Myristoyl/palmitoyloxostearamide/arachamide MEA)
잔탄검 (Xanthan gum) 0.05 토코페릴아세테이트 (Tocopheryl acetate) 0.10 메틸벤질메틸벤크이미다콜피페리디닐페탄온 (Methylbenzylmethy 0.05 lbenzimidazolepiperidinylmethanone)
피토스테롤 (Phytosterol) 0.05 아르기닌 (Arginine) 0.00 카보머 (Carbomer) 0.20 암모늄아크릴로일디메틸타우레이트비닐피를리돈공중합체 0.05 (Ammonium Acryloyldimethyltaurate/VP Copolymer ) ᅵ Total 100
[45] 거서마우스모템의체장
[46] 건선유발마우스제작을위해 7주령암컷마우스 (Balb/c)를일주일간항온및 항습조건에서적응시킨후 8주령의마우스를준비하였다.마우스의둥쪽털을 제모하고오전,오후두번이미퀴모드 (imiquimod, Aldara®) 5%크림 62.5mg을 등과오른쪽귀에도포하여감작시켰다. 2일후부터이미퀴모드 5%크림을매일 62.5mg씩등과오른쪽귀에 5일동안도포하였다.실험시작 8일째되는날체중， 피부수분증발량 (trans epidermal water loss, TEWL),피부수분량 (hydration),등과 귀의피부두께를측정하여건선유발마우스를확인하였다.
[47]
[48] 비교예 1~2및심시예 1~5의선정
[49] 마우스의체중，피부수준증발양，피부수분량,둥과귀의피부두께를측정하여 평균값이유사하게그룹을나누었다.그룹은총 7그룹으로각그룹당 5마리의 마우스를사용하였다.건선이유발되지않은정상마우스그룹인비히클 (vehicle) 그룹 1그룹 (비교예 1)과，건선이유발된마우스에아무런처리도하지않고
IMQ(Imidazoline quarternary)만을처리한그룹 1그룹 (비교예 2)을각각대조군 그룹으로정하였다.그리고，처리하는산성외용제의 pH에따라 pH 3.0외용제 처리실험군 (실시예 1), ρΗ 3.5외용제처리실험군 (실시예 2)， pH 4.0외용제처리 실험군 (실시예 3), pH 4.5외용제처리실험군 (실시예 4), pH 5.0외용제처리 실험군 (실시예 5)의서로다른 5개의실험군으로나누었다.
[50]
[51] 피부도포용산성외용제도포및상태확인
[52] 실험시작 8일째되는날부터외용제를매일등과오른쪽귀에 4일동안
도포하였다.실험시작 8일, 10일， 12일째되는날체중，피부수분증발량， 피부수분량및등과귀의피부두께를측정하여상태를확인하였으며，실험 종료일인 12일째되는날부터피부 pH，흥반 (erytheme)을측정하여상태를 확인하였다.
[53]
[54] 조직병리학적 확인
[55] 실험종료일인 12일째되는날마우스를안락사시키고등쪽피부조직과， 좌우귀조직을 6mm지름의원형으로절취하여무게를측정후 10% neutral buffered formalin에고정하였다.고정된조직을이용하여파라핀블록을 제작하고, 5um의두께로박절하여 H&E(hematoxylin & eosin)염색을진행하였다. 염색된조직을광학현미경으로확인하고 (도 12~18),표피의두께를측정하였다.
[56]
[57] 표 2 [Table 2]
— '- 8일째 10일째 12일째 ᄀ후 8일째 10일째 12일째 비교예 1 20.01 21.08 20.65 비교예 1 19.30 20.11 20.98
1 2 20.11 21.14 22.03 2 2 19.40 21.01 21.21
3 19.89 20.98 21.12 3 19.60 20.21 20.99
4 20.24 21.56 20.88 4 18.90 20.01 21.48
5 19.57 20.88 21.34 5 18.30 19.88 22.20 평균 19.96 21.13 21.20 평균 19.10 20.04 21.37 표준편 0.23 0.23 0.47 표준편 0.46 0.11 0.45 차 차
실시예 1 18.90 19.98 22.31 실시예 1 18.60 19.89 21.56
1 2 19.30 20.10 21.48 2 2 19.70 20.14 20.98
3 20.10 21.03 21.21 3 19.30 20.34 20.77
4 18.10 19.88 21.88 4 19.10 20.45 22.78
5 17.60 19.22 21.56 5 19.10 20.14 21.45 평균 18.80 20.04 21.69 평균 19.16 20.19 21.51 표준편 0.88 0.58 0.38 표준편 0.36 0.19 0.70 차 차
실시예 1 18.90 19.88 20.14 실시예 1 18.80 20.34 21.81
3 2 19.90 19.99 22.21 4 2 19.40 20.54 21.54
3 19.20 20.87 22.22 3 19.70 20.62 21.03
4 19.60 20.17 22.04 4 19.30 20.81 21.35
5 19.10 20.42 21.08 5 19.40 20.14 21.55 평균 19.34 20.27 21.54 평균 19.32 20.48 21.46 표준편 0.36 0.35 0.82 표준편 0.29 0.23 0.26 차 차
Figure imgf000010_0001
[58] 표 2및도 1은마우스의체중 (g)을나타는것으로 IMQ를처리한그룹에서 약간의체중감소가나타났으나유의적인차이가나타날만큼감소하지않았다.
[59]
[60] 표 3
[Table 3]
—'-^ 8일째 10일째 12일째 ᄀ阜 8일째 10일째 12일째 비교예 1 5.10 6.30 6.40 비교예 1 28.90 31.80 41.20
1 2 6.90 6.70 5.10 2 2 32.80 38.80 40.30
3 2.20 8.10 5.80 3 39.50 35.606 39.90
4 8.80 5.50 5.40 4 33.60 34.20 34.80
5 5.80 7.30 6.10 5 30.30 33.30 38.40 평균 6.36 6.78 5.76 평균 33.02 34.74 38.92 표준편 1.38 0.88 0.47 표준편 3.65 2.38 2.25 차 차
실시예 1 33.50 29.30 25.30 실시예 1 35.40 28.30 20.40
1 2 30.70 28.80 26.70 2 2 33.10 30.10 18.40
3 33.20 27.60 24.30 3 31.20 29.80 21.30
4 36.70 30.10 25.60 4 32.80 28.70 19.10
5 32.00 29.90 24.70 5 35.20 29.30 17.30 평균 33.22 29.14 25.32 평균 33.54 29.24 19.30 표준편 2.00 0.90 0.83 표준편 1.58 0.67 1.42 차 차
실시예 1 35.80 19.80 15.40 실시예 1 34.50 24.50 18.80
3 2 29.80 20.60 18.30 4 2 32.40 23.50 19.10
3 34.20 20.30 19.10 3 32.10 24.90 18.80
4 33.80 19.80 17.30 4 33.10 23.40 18.40
5 30.30 20.70 18.80 5 33.50 23.50 19.30 평균 32.78 20.24 17.78 평균 33.12 23.96 18.88 표준편 2.33 0.38 1.34 표준편 0.85 0.62 0.31 차 차
Figure imgf000012_0001
표 3및도 2는피부수분증발량 (g/cnf/hr)을확인한것으로 IMQ를처리한비교예 2는 8일째에비교예 1보다피부수분증발량이 5배이상증가하였고，실시예 2， 실시예 3및실시예 4에서정상에가까운수치가나타났으며，실시예 3에서가장 효과가우수하였다.실시예 1~5모두에서유의성있는증가를확인하였다.
[62]
[63] 표 4
[Table 4]
Figure imgf000013_0001
Figure imgf000014_0001
[64]
[65] 표 4및도 3은피부수분함유량 (A.U)을나타내는것으로 IMQ를처리한비교예 2는비교예 1보다 3배이상피부수분함유량이감소하였고,실시예 2,실시예 3및 실시예 4에서정상에가까운수치가나타났으며，실시예 3에서가장효과가 우수하였다.실시예 1~5모두에서유의성있는증가를확인하였다.
[66]
[67] 표 5
[Table 5]
8일째 10일째 12일째 ᄀ阜 8일째 10일째 12일째 비교예 1 0.22 0.23 0.24 비교예 1 0.77 0.80 0.79
1 2 0.21 0.21 0.23 2 2 0.68 0.71 0.78
3 0.19 0.22 0.23 3 0.71 0.68 0.76
4 0.21 0.23 0.21 4 0.73 0.66 0.69
5 0.23 0.20 0.22 5 0.69 0.67 0.67 평균 0.21 0.22 0.23 평균 0.72 0.70 0.74 표준편 0.01 0.01 0.01 표준편 0.03 0.05 0.05 차 차
실시예 1 0.68 0.55 0.49 실시예 1 0.73 0.51 0.36
1 2 0.69 0.61 0.51 3 2 0.74 0.48 0.33
3 0.71 0.57 0.45 3 0.75 0.48 0.35
4 0.77 0.58 0.53 4 0.81 0.56 0.37
5 0.73 0.60 0.40 5 0.64 0.44 0.41 평균 0.72 0.58 0.48 평균 0.73 0.49 0.36 표준편 0.03 0.02 0.05 표준편 0.05 0.04 0.03 차 차
실시예 1 0.69 0.49 0.33 실시예 1 0.68 0.53 0.33
3 2 0.78 0.48 0.31 4 2 0.78 0.51 0.29
3 0.69 0.51 0.35 3 0.81 0.49 0.41
4 0.71 0.44 0.37 4 0.71 0.61 0.44
5 0.77 0.39 0.28 5 0.66 0.58 0.38 평균 0.73 0.45 0.33 평균 0.73 0.54 0.37 표준편 0.04 0.04 0.03 표준편 0.06 0.04 0.05 차 차
Figure imgf000016_0001
[68] 표 5및도 4은둥두께^ m)를측정한것으로 IMQ를처리한비교예 2는비교예 1보다 3배이상두꺼워졌고，실시예 2，실시예 3및실시예 4에서정상에가까운 두께가나타났으며，실시예 3에서가장효과가우수하였다.실시예 1~5모두에서 유의성있는감소를확인하였다.
[69]
[70] 표 6
[Table 6]
왼쪽 오른쪽
그룹 8일째 10일째 12일째 8일째 10일째 12일째 비교예 1 1 0.07 0.06 0.07 0.07 0.07 0.07
2 0.07 0.07 0.07 0.07 0.07 0.07
3 0.07 0.07 0.07 0.07 0.07 0.07
4 0.07 0.07 0.07 0.07 0.07 0.07
5 0.07 0.07 0.07 0.07 0.06 0.07 평균 0.07 0.07 0.07 0.07 0.07 0.07 표준편차 0.00 0.00 0.00 0.00 0.00 0.00 비교예 2 1 0.07 0.07 0.07 0.22 0.21 0.24
2 0.07 0.07 0.07 0.23 0.21 0.24
3 0.06 0.07 0.07 0.24 0.25 0.25
4 0.07 0.07 0.07 0.22 0.26 0.23
5 0.07 0.07 0.07 0.24 0.24 0.22 평균 0.07 0.07 0.07 0.23 0.23 0.24 표준편차 0.00 0.00 0.00 0.01 0.02 0.01 실시예 1 1 0.07 0.06 0.07 0.23 0.21 0.18
2 0.07 0.07 0.07 0.23 0.21 0.18
3 0.07 0.07 0.06 0.21 0.22 0.17
4 0.07 0.07 0.07 0.22 0.21 0.17
5 0.07 0.07 0.07 0.23 0.22 0.16 평균 0.07 0.07 0.07 0.22 0.21 0.17 표준편차 0.00 0.00 0.00 0.01 0.00 0.01 실시예 2 1 0.07 0.07 0.07 0.24 0.21 0.16
2 0.07 0.07 0.06 0.23 0.20 0.16
3 0.07 0.07 0.07 0.23 0.22 0.14
4 0.07 0.06 0.07 0.21 0.21 0.16
5 0.07 0.07 0.07 0.22 0.19 0.18 평균 0.07 0.07 0.07 0.23 0.21 0.16 표준편차 0.00 0.00 0.00 0.01 0.01 0.01 실시예 3 1 0.07 0.07 0.07 0.22 0.20 0.15
2 0.06 0.07 0.07 0.24 0.19 0.12
3 0.07 0.07 0.07 0.23 0.20 0.12
4 0.07 0.06 0.07 0.22 0.21 0.13
5 0.07 0.07 0.07 0.21 0.21 0.15 평균 0.07 0.07 0.07 0.22 0.20 0.13 표준편차 0.00 0.00 0.00 0.01 0.01 0.01 실시예 4 1 0.07 0.06 0.07 0.22 0.20 0.13
2 0.07 0.07 0.07 0.24 0.20 0.14
3 0.07 0.07 0.07 0.25 0.21 0.14
4 0.07 0.07 0.07 0.21 0.20 0.15
5 0.07 0.07 0.07 0.21 0.21 0.15 평균 0.07 0.07 0.07 0.23 0.20 0.14 표준편차 0.00 0.00 0.00 0.02 0.00 0.01 실시예 5 1 0.07 0.06 0.07 0.21 0.21 0.18
2 0.07 0.07 0.07 0.23 0.21 0.18
3 0.07 0.07 0.07 0.23 0.22 0.19
4 0.07 0.07 0.07 0.24 0.20 0.17
5 0.07 0.07 0.07 0.21 0.19 0.20 평균 0.07 0.07 0.07 0.22 0.21 0.18 표준편차 0.00 0.00 0.00 0.01 0.01 0.01 표 6및도 5은귀두께 0^1)를측정한것으로왼쪽귀는처리하지않고 대조군으로하였다 . IMQ를처리한비교예 2는비교예 1보다 3배이상
두꺼워졌고，실시예 3및실시예 4에서정상에가까운두께가나타났으며, 실시예 3에서가장효과가우수하였다.실시예 1~5모두에서유의성있는감소를 확인하였다.
[72]
[73] 표 7 [Table 7]
Figure imgf000019_0001
표 7및도 6은실험종료후등조직을채취하여무게 (mg)를측정한것으로, 실시예 1~5에서 IMQ를처리한비교예 2보다무게가감소하였다.실시예 2， 실시예 3및실시예 4에서정상에가까운수치가나타났으며，실시예 3에서가장 효과가우수하였다.실시예 1~5모두에서비교예 2와비교하였을때유의성있는 감소를확인하였다.
[75]
[76] 표 8
[Table 8]
Figure imgf000021_0001
Figure imgf000022_0001
표 8및도 7은실험종료후귀조직을채취하여무게 (mg)를측정한것으로 오른쪽귀를통해비교하였을때실시예 1~5는11 (3를처리한비교예 2보다 무게가감소하였다.실시예 2，실시예 3및실시예 4에서정상에가까운수치가 나타났으며，실시예 1~5모두에서비교예 2와비교하였을때유의성있는감소를 확인하였다.
[78]
[79] 표 9
[Table 9]
Figure imgf000023_0001
[80] 표 9및도 8은피부의 pH를나타낸것으로,실시예 1~5에서 pH가감소하였고, 실시예 5를제외하고는모두유의성있는감소를나타냈으며，실시예 3에서가장 정상에가까운수치가나타났다.
[81]
[82] 표 10
[Table 10]
Figure imgf000025_0001
[83] 표 10및도 9는색차계를사용하여흥반 (erythema)정도를측정한것으로,발적 정도는육안으로구분하기힘드나수치상으로감소하였으며，실시예 3및 실시예 4에서유의성이나타났다.
[84]
[85] 표 11
[Table 11]
그룹 지점 1 지점 2 지점 3 지점 4 지점 5 지점 5 총 평균 비교예 1 1 11.3 10.3 11.8 12.6 12.2 9.6 11.1
2 13.5 9.7 9.1 11.6 8.4 11.6
3 10.1 10.5 13.4 9.9 12.1 10.5
4 12.4 10.8 11.6 12.3 9.1 11.3
5 11.3 12.1 11.7 11.8 12.3 9.4 비교예 2 1 90.2 77.2 81.5 67.8 98.7 93 75.3
2 96.7 77.1 71.2 78.6 71.7 81.3
3 67.2 65.7 61.8 80.3 61.4 62.5
4 64.5 66.5 68.8 61 66.2 71.2
5 77.3 68.7 90.3 78.4 80.7 81.3 실시예 1 1 26.3 24.7 28.9 30.1 33.5 19.1 30.2
2 18.4 28.3 25.3 24.7 21.6 26.9
3 25.3 30.3 34.4 38.9 37.6 33.3
4 35.6 34.2 33.3 32.8 31.8 29.5
5 33.6 37.1 31.2 33 35.7 30.3 실시예 2 1 26.8 25.4 21.8 29.4 18.3 15.6 24.8
2 27 27.9 26.8 28.3 30.1 27.4
3 20.5 21.3 25.5 28.9 26.3 27.1
4 22.1 23.3 25.3 18.9 21.3 27.1
5 26.4 25.3 25.5 25.1 27.1 23.3 실시예 3 1 21.6 23.1 23.8 22.8 25.1 22.5 23.5
2 28.8 22.7 22.1 22.8 20.8 18.9
3 27.9 16.6 15.3 23.5 25 29.1
4 19.4 26.4 23.9 23.3 23.4 24.1
5 23.4 25.6 27.1 21.3 28.6 25.4 실시예 4 1 26.3 25.8 24.1 30.3 33.1 18.9 25.0
2 16.1 29.8 25.3 26.7 26.6 20
3 25.3 30.1 27.4 24.3 25.1 28.3
4 26.4 21.3 25.3 28.1 24.1 20.3
5 20.4 21.3 22.8 25 22.6 28.8 실시예 5 1 30.8 32.7 33.4 33.8 30.9 36 32.8
2 35.8 31.3 30.2 30.1 27.2 35.3
3 31.2 30.3 32.1 38.8 29.8 33.3
4 34.4 33.4 34.5 31.7 33.4 36.1
5 30.1 35.3 39.6 28.7 31.5 33.3 표 11및도 10은 H&E염색을통해둥표피두께 ( n)를나타낸것으로,염색한 둥조직샘플의사진촬영후서로다른 6개의지점에서표피층의두께를 측정하였다. IMQ를처리한비교예 2와비교하여실시예 1~5는유의성있는 감소를보였고,실시예 3，실시예 4및실시예 5에서정상에가까운수치가 나타났으며，실시예 3에서가장우수한효과를확인하였다. 표 12
[Table 12]
그룹 지점 1 지점 1 지점 3 지점 4 지점 5 지점 6 총평균 비교예 1 1 9.3 11.4 10.8 11.6 9.1 13.5 10.7
2 11.4 11.6 10.9 8.8 10.6 9.7
3 11.6 10.8 12 11.7 10.4 10.8
4 11.1 12.3 10.8 10.5 9.8 10.6
5 10.4 11.2 10.8 9.4 8.1 10.5 비교예 2 1 63.4 52.1 58.3 54.1 57.1 60.3 53.1
2 48.4 47.1 57.2 52.3 50.4 51.6
3 53.6 53.4 51.8 57.1 58.3 50.4
4 49.6 48.8 50.3 52.7 54.1 50.9
5 52.1 53.7 58.1 45.3 50.3 50.3 실시예 1 1 40.3 38.5 35.1 36.4 34.7 33.1 36.7
2 36.3 34.2 31.2 35.3 33.7 33.8
3 30.8 36.9 34.2 41.3 42.6 39.8
4 36.4 35.1 33.8 38.9 38.4 35.3
5 37.8 38.5 39.9 40.5 40.3 38.1 실시예 2 1 32.2 31.3 30.5 36 34.5 33.3 32.8
2 35.1 35.2 36.4 37.1 35.2 33.3
3 30.1 28.5 40.3 30.5 31.2 31.2
4 33.4 35.1 30.5 30.9 31.4 33.7
5 29.5 30.4 34.1 32.5 30.3 30 실시예 3 1 33.3 32.1 28.9 35.4 30.1 32.7 31.2
2 29.8 30.3 28.7 29.6 30.3 31.5
3 33.2 31.5 30.8 31.6 32 32.8
4 30.7 31.3 29.8 32.3 33.3 31
5 28.5 31.2 30.8 30.7 31.5 30.1 실시예 4 1 30.3 28.6 35.4 37.1 33.5 35.1 33.4
2 31.2 33.6 35.1 . 30.2 30.8 31.7
3 33.5 35.2 35.4 34.3 36.1 40.3
4 30.1 32.3 33.1 32 31.8 32.1
5 35.3 33.4 35.4 31.2 33.3 34.5 실시예 5 1 45.3 42 40.3 42.1 38.6 39.5 39.4
2 38.4 35.2 39.4 40.1 41.3 40.4
3 44.3 42.5 38.7 38.8 36.9 37.2
4 38.4 36.9 37.1 40.4 33.8 35.6
5 42.3 39.4 44.4 38.5 35.6 40
[89] 표 12및도 11은 H&E염색을통해귀표피두께 mi)를나타낸것으로，염색한 둥조직샘폴의사진촬영후서로다른 6개의지점에서표피층의두께를 측정하였다. IMQ를처리한비교예 2와비교하여실시예 1~5는유의성있는 감소를보였고，실시예 3,실시예 4및실시예 5에서정상에가까운수치가 — - 나타났으며,실시예 3에서가장우수한효과를확인하였다.
[90]
[91] 표 13
[Table 13]
Figure imgf000031_0001
Figure imgf000032_0001
I |*** P<0.00, ** P<0.01, * P<0.05, ns P>0.05
표 13은비교예 1~2및실시예 1~5에서측정한각각의정량적인측정값의 유의성을나타낸것으로，특히, IMQ만을처리한비교예 2에비해실시예 1~5는 모든값에서유의성있는효과가있었다.

Claims

청구범위
[청구항 1] 산성고분자화합물을포함하며 pH 3.0내지 5.0인건선치료용 외용제조성물.
[청구항 2] 제 1항에있어서，
상기 pH는산성고분자화합물의함량에따라조절되는것을 특징으로하는건선치료용외용제조성물.
[청구항 3] 제 2항에있어서,
상기산성고분자화합물은카보머또는카보폴인건선치료용 외용제조성물.
[청구항 4] 제 1항내지 3항중어느한항에있어서，
상기조성물은로션，크림，겔，연고，고약，에멀견,용액，에어로졸 및페이스트로이루어진군으로부터선택되는형태인건선치료용 외용제조성물.
PCT/KR2015/010191 2014-09-29 2015-09-25 건성 치료용 산성 외용제 조성물 WO2016052947A1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20140129986 2014-09-29
KR10-2014-0129986 2014-09-29

Publications (1)

Publication Number Publication Date
WO2016052947A1 true WO2016052947A1 (ko) 2016-04-07

Family

ID=55630913

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2015/010191 WO2016052947A1 (ko) 2014-09-29 2015-09-25 건성 치료용 산성 외용제 조성물

Country Status (2)

Country Link
KR (1) KR20160037791A (ko)
WO (1) WO2016052947A1 (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190133932A (ko) * 2018-05-24 2019-12-04 주식회사 명진뉴텍 트로폴론 및 피씨에이 에틸 코코일 알지네이트 또는 글리세릴 운데실네이트를 유효성분으로 포함하는 화장료 보존용 조성물 및 이를 함유하는 화장품

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5061486A (en) * 1987-12-22 1991-10-29 Drythanol Ltd. Dithranol composition containing no oily ingredients
US20030199591A1 (en) * 2002-04-23 2003-10-23 Bradley Pharmaceuticals, Inc. Novel carbamide peroxide compositions for the treatment of dermatological disorders and methods for their use
KR20100049162A (ko) * 2008-11-03 2010-05-12 제일약품주식회사 천연오일을 활성성분으로 함유하는 관절염치료제용 약제학적 겔형 조성물 및 그 제조방법
KR20120129878A (ko) * 2009-11-19 2012-11-28 갈더마 래보라토리즈 엘피 건선의 치료 또는 예방을 위한 알파 2 아드레날린성 수용체 효능제의 용도
KR20130101549A (ko) * 2010-10-21 2013-09-13 갈데르마 소시에떼아노님 브리모니딘 겔 조성물 및 사용 방법

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5061486A (en) * 1987-12-22 1991-10-29 Drythanol Ltd. Dithranol composition containing no oily ingredients
US20030199591A1 (en) * 2002-04-23 2003-10-23 Bradley Pharmaceuticals, Inc. Novel carbamide peroxide compositions for the treatment of dermatological disorders and methods for their use
KR20100049162A (ko) * 2008-11-03 2010-05-12 제일약품주식회사 천연오일을 활성성분으로 함유하는 관절염치료제용 약제학적 겔형 조성물 및 그 제조방법
KR20120129878A (ko) * 2009-11-19 2012-11-28 갈더마 래보라토리즈 엘피 건선의 치료 또는 예방을 위한 알파 2 아드레날린성 수용체 효능제의 용도
KR20130101549A (ko) * 2010-10-21 2013-09-13 갈데르마 소시에떼아노님 브리모니딘 겔 조성물 및 사용 방법

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190133932A (ko) * 2018-05-24 2019-12-04 주식회사 명진뉴텍 트로폴론 및 피씨에이 에틸 코코일 알지네이트 또는 글리세릴 운데실네이트를 유효성분으로 포함하는 화장료 보존용 조성물 및 이를 함유하는 화장품
KR102065732B1 (ko) 2018-05-24 2020-02-11 주식회사 명진뉴텍 트로폴론 및 피씨에이 에틸 코코일 알지네이트 또는 글리세릴 운데실네이트를 유효성분으로 포함하는 화장료 보존용 조성물 및 이를 함유하는 화장품

Also Published As

Publication number Publication date
KR20160037791A (ko) 2016-04-06

Similar Documents

Publication Publication Date Title
KR20160014753A (ko) Ｈａｓ2-자극용 식물 추출물
CN109431873B (zh) 一种修复舒缓皮肤炎症的组合物
KR20080003909A (ko) 피부 화장료 및 주름 개선제
CA2701323A1 (en) Compositions of glucomannan cross-linked with hyaluronic acid for dermal regeneration
JP2022511023A (ja) シスツス・モンスペリエンシス（Ｃｉｓｔｕｓ ｍｏｎｓｐｅｌｉｅｎｓｉｓ）の抽出物の新規な化粧品的及び皮膚科学的使用
JP2007262012A (ja) ヒアルロン酸産生促進剤、並びにそのヒアルロン酸産生促進剤を含む皮膚外用剤、化粧料、医薬部外品、肌荒れ改善剤、及びしわ改善剤
CN115487112A (zh) 用于皮肤抗炎舒缓的组合物
US20130183257A1 (en) Compositions and methods for improving skin appearance
US6589540B1 (en) Cosmetic composition for skin care containing retinol and epidermal growth factor
EP2861239A2 (en) Topical compositions for the treatment of chronic inflammatory skin disease
DE19945484A1 (de) NO-freisetzende topisch applizierbare Zusammensetzung
CN114344231A (zh) 一种藏红花舒敏组合物及其应用
RU2698796C2 (ru) Икотиниб-содержащие местнодействующие накожные фармацевтические композиции и их применения
WO2016052947A1 (ko) 건성 치료용 산성 외용제 조성물
US20130089632A1 (en) Cosmetic Composition for Inhibiting Hair Loss and Enhanced Hair Growth
WO2021017448A1 (zh) 具有止痒功效的皮肤外用组合物
KR100964428B1 (ko) 약용식물 추출물을 포함하는 피부 염증 완화용 화장료조성물
EP3903793A1 (en) Pharmaceutical composition comprising clonal stem cell for prevention or treatment of atopic dermatitis
KR101954632B1 (ko) 발아 인삼씨 추출물을 함유하는 피부 외용제 조성물
KR20150037204A (ko) 대복피 추출물 포함 창상 치유용 조성물
WO2019138291A2 (en) Cerdulatinib-containing topical skin pharmaceutical compositions and uses thereof
JP7396585B2 (ja) Ｔｓｌｐ遺伝子発現抑制用、ｉｌ－３３遺伝子発現抑制用、又はフィラグリン産生促進用組成物
WO2021235275A1 (ja) ヒアルロン酸産生促進剤およびコラーゲン産生促進剤
KR102465464B1 (ko) 비타젠을 포함하는 헤어케어용 조성물
US11413313B2 (en) Pharmaceutical composition for preventing or treating atopic dermatitis comprising clonal stem cells

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15845625

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15845625

Country of ref document: EP

Kind code of ref document: A1